Targeted radiation zaps Hard-to-Treat cancers in early trial

NCT ID NCT06376253

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Participants must have already tried at least one other treatment without success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [177Lu]Lu-EVS459
What this could lead to: If successful, this could provide a new targeted treatment option for people with advanced ovarian or lung cancers that have not responded to other therapies.
What could go wrong: This is a very early phase 1 trial with only 4 participants, so safety and effectiveness are not yet established. The treatment involves radiation and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HIGH-GRADE SEROUS OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm malignant ovarian serous tumor non-small cell lung carcinoma ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER OVARIAN CANCER

Contacts and locations

Locations

Novartis Investigative Site

Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.